0
Stopping Pharma’s Ripoffs and Drug Savings For All Act
3/1/2025, 4:38 AM
Summary of Bill HR 890
The main goal of this bill is to prevent double patenting by establishing new rules and regulations within the patent system. By doing so, the bill aims to promote fairness and efficiency in the patent process, ultimately benefiting inventors, businesses, and consumers.
In addition to addressing double patenting, the bill also includes provisions for other purposes related to patent law. These additional purposes may include clarifying existing patent laws, improving patent examination procedures, and enhancing the overall effectiveness of the patent system. Overall, Bill 119 HR 890 seeks to make important changes to the patent system in order to prevent double patenting and improve the overall functioning of the patent process. It is an important piece of legislation that aims to protect the integrity of the patent system and promote innovation in the United States.
Congressional Summary of HR 890
Stopping Pharma’s Ripoffs and Drug Savings For All Act
This bill addresses double patenting with respect to drug-related patents. Specifically, the bill requires an owner of drug-related patents, if the owner lists more than one patent as covering a particular drug, to prove in certain proceedings that each patent covers a distinct invention. If the patent owner fails to do so, then the owner shall have disclaimed patent protection from all the listed patents after the first patent expires.
This requirement shall apply to various proceedings challenging the validity of drug-related patents, as well as to infringement lawsuits filed by the patent owner against companies seeking Food and Drug Administration approval for generic or biosimilar versions of patented drugs.
The bill also directs the U.S. Patent and Trademark Office (USPTO) to review its examination procedures to prevent granting multiple patents for the same drug or biological product, unless the patents cover distinct inventions. The USPTO shall report to Congress its findings and recommendations from the review.
Read the Full Bill
Current Status of Bill HR 890
Bipartisan Support of Bill HR 890
Total Number of Sponsors
2Democrat Sponsors
2Republican Sponsors
0Unaffiliated Sponsors
0Total Number of Cosponsors
0Democrat Cosponsors
0Republican Cosponsors
0Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill HR 890
Primary Policy Focus
Alternate Title(s) of Bill HR 890
Comments

Jalen Ford
9 months ago
I don't know much about this bill, but if it helps lower drug prices, then I'm all for it.
